title: Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.
authors.affiliation: American University Medical Center, POB 113-6044/C-27, Beirut, Lebanon, rs01@aub.edu.lb.
authors.forename: R
authors.initials: R
authors.lastname: Sawaya
authors.forename: W
authors.initials: W
authors.lastname: Radwan
authors.forename: S
authors.initials: S
authors.lastname: Hammoud
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D016889:Endometrial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000473:pathology; D011379:Prognosis
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab